Edition:
United Kingdom

NanoCarrier Co Ltd (4571.T)

4571.T on Tokyo Stock Exchange

689JPY
24 Apr 2018
Change (% chg)

-- (--)
Prev Close
¥689
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
1,729,607
52-wk High
¥1,337
52-wk Low
¥618

Latest Key Developments (Source: Significant Developments)

NanoCarrier signs license preferential negotiating rights agreement with AccuRna
Monday, 4 Dec 2017 

Dec 4 (Reuters) - NanoCarrier Co Ltd <4571.T> ::Says it and AccuRna Inc entered into a preferential negotiating rights agreement on exclusive right to license of drug development based on co's gene delivery technology.Co will get payment from AccuRna according to the agreement.Co also plans to inject capital into AccuRna Inc .  Full Article

VBL Therapeutics and Nanocarrier signs agreement for VB-111 in Japan
Monday, 6 Nov 2017 

Nov 6 (Reuters) - Nanocarrier Co Ltd <4571.T>:VBL Therapeutics and Nanocarrier Co Ltd sign exclusive agreement for VB-111 in Japan.Vascular Biogenics Ltd - ‍Nanocarrier receives exclusive rights to VB-111 in Japan, VBLT retains rights in rest of world​.Vascular - Pursuant to agreement, VBLT to supply nanocarrier with VB-111.Vascular - Nanocarrier will be responsible for all regulatory, other clinical activities necessary for commercialization of VB-111 in Japan.Vascular - VBLT receives up-front payment of $15 million & is entitled to receive greater than $100 million in development & commercial milestone payments​.Vascular Biogenics Ltd - ‍VBLT will also receive tiered royalties on net sales in high-teens​.Vascular Biogenics Ltd - ‍Other terms of agreement not disclosed​.  Full Article

Nanocarrier signs exclusive agreement with VBL Therapeutics for VB-111 in Japan
Monday, 6 Nov 2017 

Nov 6 (Reuters) - NanoCarrier Co Ltd <4571.T>:Says co signs an exclusive license agreement with VBL Therapeutics, for the development, commercialization, and supply of ofranergene obadenovec ("VB-111") in Japan.Under terms of the agreement, VBL Therapeutics will supply the co with VB-111, and the co will be responsible for all regulatory and other clinical activities necessary for commercialization in Japan.Says VBL Therapeutics will receive up-front payment of $15 million, development and commercial milestone payments and tiered royalties on net sales from the co.  Full Article

NanoCarrier and JCR conclude collaborative research agreement for drug delivery to the brain for nucleic acid medicines
Tuesday, 10 Oct 2017 

Oct 10 (Reuters) - JCR Pharmaceuticals Co Ltd <4552.T>:* Says it and NanoCarrier Co., Ltd <4571.T> conclude collaborative research agreement for drug delivery to the brain for nucleic acid medicines .* Under this agreement, Nanocarrier and JCR will integrate the unique technologies and knowledge of both companies, and aim to develop an innovative drug effectively delivered to the brain .  Full Article

NanoCarrier says patent for nucleic acid delivery technology granted by European Patent Office
Monday, 1 Aug 2016 

NanoCarrier Co Ltd <4571.T>:Says patent related to nucleic acid delivery technology granted by the European Patent Office regarding particle composition and pharmaceutical composition.  Full Article

NanoCarrier says clinical trial of NC-6004
Wednesday, 22 Jun 2016 

NanoCarrier Co Ltd <4571.T>:Says it submitted CTA (Clinical Trial Authorization) of NC-6004 to regulatory authorities of EU regional.  Full Article

BRIEF-NanoCarrier says business and capital alliance with Gene Techno Science and Noritsu Koki

* Says it plans business and capital alliance with Gene Techno Science Co Ltd and Noritsu Koki Co Ltd, regarding biopharmaceutical related business